Teva Pharmaceutical Industries Announces Discontinuation of Emursolmin Phase 2 Clinical Trial
TEVA Teva- Pharmaceutical Industries Ltd
$43.24 +1.98%
View chart & analysis → - 1Teva Pharmaceutical Industries shares fell more than 3% in pre-market trading on Monday.
- 2The independent data monitoring committee recommended discontinuing the TOPAS-MSA clinical trial based on interim analysis results.
- 3Executive Vice President Eric Hughes said he was disappointed with the interim analysis results but remains committed to learning from the data.
So what's the key point?
Teva Pharmaceutical Industries decided to stop a drug trial it was conducting. The stock price fell by more than 3% following this news.
Source Investing.com +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.